Reduction in Natural Death and Renal Failure From a Systematic Screening and Treatment Program in an Australian Aboriginal Community by Hoy, Wendy E. et al.
Kidney International, Vol. 63, Supplement 83 (2003), pp. S66–S73
Reduction in natural death and renal failure from a
systematic screening and treatment program in an
Australian Aboriginal community
WENDY E. HOY, ZHIQIANG WANG, PHILIP R.A. BAKER, and ANGELA M. KELLY
Menzies School of Health Research, Darwin, Northern Territory, and Centre for Chronic Disease, Department of Medicine,
University of Queensland, Herston, Queensland, Australia
(NNT) to avoid one terminal event of natural causes was calcu-Reduction in natural death and renal failure from a systematic
lated at only 11.6.screening and treatment program in an Australian Aboriginal
Conclusions. Falling rates of deaths and renal failure in thecommunity.
whole community support marked benefit of the program. Mil-Background. Australian Aborigines in remote areas are ex-
lions of dollars have been saved, based on avoidance of dialysisperiencing an epidemic of renal and cardiovascular disease.
alone, but the reduction in premature death is the greater benefit.In November 1995, we introduced a renal and cardiovascular
Chronic disease programs like this are enormously effective,treatment program into the Tiwi community, which has a three-
and should be introduced into to all high-risk communities asto fivefold increase in death rates and a recent annual incidence
a matter of urgency.of treated end-stage renal disease (ESRD) of 2760 per million.
Our previous study described an estimated 50% reduction in
renal failure and all-cause natural deaths in the treatment group
through December 31, 1998. We now describe a reduction in Aborigines living in remote Australia have high ratesthese events through mid 2000.
of all-cause mortality, of cardiovascular deaths and ofMethods. People eligible for treatment were those with con-
end-stage renal failure (ESRD) [1, 2], with the incidencefirmed hypertension, diabetics with microalbuminuria or overt
albuminuria, and people with overt albuminuria, regardless of of treated ESRD exceeding 1000 per million in some
blood pressure and diabetes. Treatment centered around the regions. Costs of treating ESRD are spiraling out of con-
use of perindopril (Coversyl, Servier), with additional agents trol. From 1996 to 1998, the annualized treatment costsas needed to reach defined blood pressure goals, attempts at
for an Aboriginal person on hemodialysis in the Topcontrol of glucose and lipid levels, and health education. Two
End of the Northern Territory (NT) were estimated athundred and sixty-seven people, or 30% of the adult popula-
tion, have been enrolled, with mean follow up of 3.39 years. $112,169:$71,000 for dialysis treatments alone and
Rates of terminal endpoints were compared on an intention- $41,169 for intercurrent hospitalizations [3]. These funds
to-treat basis with those of 327 historical controls matched for could be spent otherwise on prevention and primary carebaseline disease severity, who were followed for a mean of
in this seriously under-resourced environment. However,3.18 years in the pre-treatment program era, against a back-
premature death in young and middle aged adults is theground of no treatment or inconsistent changing treatment.
Results. Terminal events occurred in 38 controls and 23 peo- greater tragedy.
ple in the treatment group. The estimated rate of natural deaths These problems have been especially serious in the
in the treatment group was 50% that of the controls, (P 0.012); Tiwi Islands (population about 1800, about 50% age 20the rate of renal deaths was 47% (P  0.038) and the rate of
years), with high rates of premature adult death, and annon-renal deaths was 54% that of controls (P 0.085). Survival
incidence of treated ESRD reaching 2760 per million inbenefit in the treatment group was observed at all levels of overt
albuminuria, in non-diabetics and diabetics, in normotensive as the mid 1990s [2]. In the 1990s, 25% of natural deaths
well as hypertensive people, and in people who had been taking in Tiwi adults were renal deaths, 42% had a primary or
angiotensin converting enzyme-inhibitors (ACEi) in the pre- underlying cardiovascular cause, and 43% were of nei-program era, as well as those who had not. Benefit was absent
ther renal nor cardiovascular cause [4].among the low death rates of people without overt albuminuria,
In a community-wide screening program starting inand questionable among people with glomerular filtration rates
(GFRs) 60 mL/min. The number of people needed to treat 1990, we found cardiovascular risk factors, including type
2 diabetes and hypertension, in abundance [5]. We also
found that renal disease, marked by pathologic albumin-Key words: kidney disease, Tiwi and disease, community renal pro-
uria, was pervasive. Albuminuria progressed with age, sogram, diabetes, hypertension, cardiovascular disease, albuminuria:cre-
atinine ratio, end-stage renal disease. that fully 55% of adults were affected, and was inversely
correlated with glomerular filtration rate (GFR) [6]. A 2003 by the International Society of Nephrology
S-66
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longitudinal study showed that albuminuria marked all increased to 8 mg for people above the blood pressure
goal, and later in the program, for people of substantialthe future risk for renal deaths, and it also strongly pre-
dicted non-renal deaths, both cardiovascular and non- body size, or with resistant overt albuminuria (ACR 60
g/mol and more). After the first year we used full-doserenal non-cardiovascular. Overall, pathologic albumin-
uria marked 75% of the risk for all-case natural death perinopril in people with serious renal insufficiency, find-
ing little justification for use of smaller doses [10]. Cal-over the observation period [4].
Use of antihypertensive drugs, including angiotensin cium channel blockers were added if needed for blood
pressure control, and diuretics were added for furtherconverting enzyme inhibitors (ACEi), was gradually in-
creasing in the Tiwi community through the early 1990s, blood pressure control or fluid retention. Other elements
of the program included health education, and attemptsbut systematic management of the burden of disease ex-
posed by our studies seemed beyond the capabilities of to control blood glucose levels and lipids, when needed.
Enrollment into the treatment program was prioritizedthe health services in place. Therefore, in November
1995 we introduced a formal program to alter renal and to some extent by disease severity. This included priori-
tized enrolment of several people with serious renal in-cardiovascular disease outcomes.
We previously described the results of this program sufficiency who were deteriorating on their current man-
agement. Participants were followed until they died,up through December 1998, when the maximum time
on treatment was 3.1 years, average time on treatment started dialysis, or through June 30, 2000, 4.56 years after
the first person was enrolled on the program. Peoplewas 2.1 years, and total follow up was 549 person-years
[7]. The results were dramatic: blood pressures fell mark- dying an unnatural death before the end of the observa-
tion period were censored from the cohort at the timeedly and progression of albuminuria and decline in GFR
were arrested on a group basis. When compared with of that event. Due to irresolution in the first few months
of the program, the treatment group for the final analysishistorical controls who were followed for a total of 543
years in the pre-program era, the treatment group showed included only people prescribed treatment for at least a
month.an estimated 50% fall in rates of all-cause natural deaths
After an initial training period, the program was runand renal failure.
by local health workers and community liaison workers.We now describe the survival of the treatment cohort
They used community lists and recall systems, reliedthrough June 30, 2000. Extended time on treatment has
heavily on algorithms for testing and treatment, and wereallowed a comparison with an expanded group of con-
required to become familiar with only a limited numbertrols, followed for a longer period, beginning with base-
of medicines. They were supported, mostly remotely, byline studies done earlier in the 1990s.
a nurse coordinator and a doctor authorizing treatment.
The program was modeled around collaborative, rather
METHODS than authoritative lines, and often operated outside the
The albumin creatinine ratio (ACR, g/mol) on a ran- clinic.
dom urine specimen was used as an indicator of renal It was not ethical to have an untreated control group,
disease and its severity [5, 6]. The following categories nor feasible to have one treated with different regimens;
were employed: 3.4, normal; 3.4 to 33, microalbumin- thus the outcomes of the treatment group were compared
uria, and 34, overt albuminuria. Overt albuminuria was with those of historical controls matched for disease se-
further categorized thus: 34 to 99, moderate; 100 to 199 verity, to the extent possible. These controls were people
heavy; 200 intense. Serum creatinine levels were mea- screened and followed in the pre-treatment-program era,
sured, and GFR was estimated by the Cockcroft and who were selected, blind to their ultimate outcome, based
Gault formula [8]. on the following criteria on their baseline screening:
People eligible for treatment were those with con-
firmed hypertension (140/90 on two occasions), all dia- (1) BP 140/90 and diabetes or pathologic albumin-
betics with confirmed pathologic albuminuria (ACR 3.4 uria (3.4).
g/mol and above), and all persons with confirmed overt (2) Diabetics with pathologic albuminuria (ACR 3.4).
albuminuria, (ACR 34), regardless of blood pressure (3) Overt albuminuria (ACR 34) regardless of blood
or diabetes. Exclusions were people who were pregnant, pressure or diabetes.
breast feeding or known to be allergic to ACEi.
Medical treatment centered around the use of the long- People with a single observation of elevated blood
acting angiotensin-converting enzyme inhibitor, perindo- pressure, but without other risk factors, were not included
pril (Coversyl, Servier), and attempts to keep blood pres- as controls.
sures below 130/85 in the first two years of the program, The course of controls was followed against a back-
and below 125/70 in the last two years [9]. The intended ground of no treatment or changing treatment, from
their baseline examination until they died, started dial-minimum perindopril dose was 4 mg, but the dose was
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Table 1. Characteristics of control and treatment groups
Controls, N  327 Intention to treat, N  267 P value
Age 21–76, 41.7 (12.8) 21–77, 43.4 (11.4) 0.09
Female 176/327, 53.8% 155/267, 53.0% 0.30
BMI 14.0–43.5, 25.8 (5.2) 14.9–44.1, 27.0 (5.8) 0.011
SBP mm Hg 76–220, 134.2 (21.4) 88–210, 134 (20.8) 0.93
DBP mm Hg 45–130, 82.4 (14.8) 45–120, 81.2 (13.8) 0.318
Hypertensiona 177/327, 54.1% 146/267, 54.7% 0.893
Diabetic 102/327, 31.1% 117/267, 43.8% 0.002
ACR g/mol 0.7–664, 33.1 (33–44)b 0.7–864, 45.1 (38–54)b 0.068
ACR 34 120/327, 36.7% 96/265, 36.2% 0.171c
ACR 34–99 132/327, 40.3% 89/265, 33.6%
ACR 100–199 47/327, 14.4% 47/265, 17.7%
ACR 200 28/327, 8.7% 33/265, 12.5%
Creatinine umol/L 33–596, 84.9 (82–88)b 44–380, 87.2 (84–90)b 0.33
GFR mL/min 9–212, 96.8 (35.2) 18–213, 95.7 (37.4) 0.70
GFR 30 mL/min 54/323, 16.7% 38/265, 14.3% 0.43
Data are range, mean (SD), or N (%).
a Hypertension: BP 140/90, or on ACEi treatment prior
b Geometric mean (95% CI)
c P value for difference in distribution of category of ACR
ysis, were established for at least a month in the treat- the treatment program on June 30, 2000; 23 people had
ment program, or until June 30, 2000. Survivors were died or developed renal failure, one died a suicide death,
censored 4.56 years after their qualifying observation, six became normotensive, two were “false starts”, six
the maximum follow-up period of people in the treat- became pregnant, one was breast feeding, six had ad-
ment program. People who died unnatural deaths before verse effects (3 with cough, 2 with angioedema, 1 with
4.56 years of follow-up were right-censored at time of itching), six decided to quit, three moved, and two went
death. onto palliative care.
The fate of all persons was ascertained, and a cause Three hundred and twenty-seven people were identi-
of death allocated by review of clinic and hospital records fied as controls. They were followed for a total of 1041
and death certificates. Deaths were categorized as all- years, with a mean of 3.18 (1.48) years. One hundred
cause natural death (non-renal and renal deaths), renal and seventy-one (52.3%) were ultimately enrolled in the
deaths (dialysis or death with chronic renal failure), non- treatment program. The other 156 were not, for reasons
renal deaths, cardiovascular deaths (primary or contrib- that included interim death or renal failure, declining
uting), and non-renal, non-cardiovascular deaths. These treatment, failure to confirm eligibility criteria, presence
are described in more detail elsewhere [4]. For renal of exclusion criteria, or moving from the area.
deaths and for the combined end point of natural death The profiles of the treatment and control groups are
and renal failure, the survival interval of people starting compared in Table 1. The treatment group tended to be
dialysis ended when treatment began. older than the controls, was more often diabetic, and
For the treatment cohort, data were analyzed on an tended to have higher ACR levels. Sixty-one of the treat-
“intention to treat” basis. Terminal events were ex- ment group, or 22.8%, had been prescribed enalapril or
pressed as rates per 100 person-years. Hazard ratios for captopril prior to enrollment.
terminal events were calculated by the Cox proportional Medical treatment intensified over time. Of people
hazard method after demonstration that the assumptions participating at three years, 2% were prescribed 2 mg
of the proportional hazard model were not violated. Sur- perindopril, 32% were prescribed 4 mg perindopril and
vival statistics also were compared by Kaplan Meier
66% were prescribed 8 mg perindopril. Seventeen per-
methods. STATA statistical software was used for data
cent of people (all on maximum perindopril) were takinganalysis [11].
a single additional medicine (calcium channel blockers
or diuretics) and 5.7% were taking both agents. By self-
RESULTS report in the middle and later parts of the program, 66%
of people were taking their medicines “most of the time,”Two hundred and sixty-seven people were enrolled in
27% “sometimes” or “occasionally”, and 7% “rarely orthe treatment program, or about 30% of all adults (20
never” [12].years). Baseline urine ACR levels and serum creatinine
Over the course of treatment, there was a rapid, marked,levels were available in 265 of these people. They were
and sustained drop in blood pressure, and a retardationfollowed for a total of 898 years, with a mean (SD) of
3.36 (SD 1.16) years. Fifty-six people were no longer in of both the progression of albuminuria and the loss of
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the treatment group, and a 57% reduction in renal
deaths, both of which are significant. It also shows a 46%
reduction in non-renal deaths, a 49% reduction in deaths
with a cardiovascular component, and a 61% reduction
in non-renal, non-cardiovascular deaths, although these
associations escaped significance.
Table 4 shows the estimated reduction in all-cause
natural death in the treatment group according to partici-
pant characteristics and baseline renal function, with ad-
justment for age and sex and ACR. Although the smaller
numbers reduce the significance of the associations, there
was a suggestion of treatment benefit in people with
elevated blood pressures as well as those with lower
blood pressures, in non-diabetics as well as diabetics, and
in people who had previously been on ACEi treatment as
well as those who had not. The data confirm lack of
benefit in people without overt albuminuria. Among
Fig. 1. Rates of all-cause natural death, by baseline albuminuria:creati-
people with ACRs 34 there was a 57% reduction innine ratio (ACR) category for controls ( ) versus treatment cohort ( ).
rates of natural death, which was significant.
Survival benefit of treatment took about two years to
become manifest as shown in Figure 2.
GFR on a group basis. These observations are described Figure 3 shows that the numbers of natural deaths and
separately [7, 12–14]. of the people starting dialysis in the entire community
Sixty-one people reached a terminal event of natural began to fall at about the time of enrollment of substan-
cause: 38 in the control group, and 23 in the treatment tial numbers of people in the treatment program. Aggre-
group. Twenty-five (41%) of these were renal deaths, of gate data from other Aboriginal communities across the
whom 21 went onto dialysis. Thirty-six deaths (59%) Top End of the NT, where screening and treatment poli-
were non-renal. Twenty-nine deaths (45.9%) had a pri- cies are changing more slowly, have not reflected the
mary or underlying cardiovascular cause. same sharp changes.
Figure 1 summarizes the treatment program effect. It
shows that rates of all-cause natural deaths were strongly
DISCUSSIONrelated to baseline ACR category, and that rates were
The introduction of a systematic screening and treat-lower in the treatment group than in controls for persons
ment program into this high risk community was associ-in every category of overt albuminuria. No difference
ated with an estimated 50% reduction in rate of naturalwas apparent among the low death rates of people with
deaths and 57% reduction in rate of renal failure at anlower ACRs.
average follow up of 3.39 years, when compared withTable 2 shows the numbers and rates of terminal
the fate of people with similar disease severity in theevents by baseline ACR in the control and treatment
pre-treatment program era.groups. It shows lower rates of all-cause natural death
Heightened awareness, health education, and betterfor the treatment groups in all categories of overt albu-
metabolic management were all elements of the pro-minuria, illustrated in Figure 1. It also shows the numbers
gram, but most of the treatment benefit was probablyand rates by category of death, with people with ACR
due to medication for renal and cardiovascular protec-100 consolidated into a single group, due to smaller
tion. The fall in blood pressures, the reduced progressionnumbers of type-specific events. All renal deaths but one
of ACR, and reduction in the loss of GFR, predict reduc-were segregated among people with baseline ACR 100
(the other with a baseline ACR of 99.5), and the rate in tions in renal and all-cause natural deaths, as we have
observed.the treatment group was apparently lower than in con-
trols. Rates of non-renal deaths, cardiovascular deaths There are many problems with the methods used to
estimate treatment benefit in this program. One seriousand non-renal non-cardiovascular deaths were lower also
for the treatment group than for controls in aggregate, source of understatement of treatment benefit was the
intentional recruitment into the treatment group of sev-and for people in both categories of overt albuminuria.
Table 3 summarizes the hazard ratios of the treatment eral people with progressive renal insufficiency who were
failing their status quo management. This reduced thegroup relative to controls, for each category of endpoint,
adjusted for age, sex and baseline ACR level. It shows real rates of renal failure in the natural history and exac-
erbated rates of renal failure early in the treatment pro-a 50% reduction in rates of all-cause natural deaths in
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Table 2. Terminal events in controls versus treatment group
Controls Treatment
Natural endpoints ACR Controls events/100 person-year Treatment events/100 person-year
by category category events/person-year (95% CI) events/person-year (95% CI)
All cause All 38/1041.2 3.64 (2.66–5.05) 23/897.8 2.56 (1.73–3.92)
34 3/422.4 0.71 (0.23–2.20) 3/310.6 1.00 (0.31–3.0)
34–99 15/417.1 3.60 (2.17–5.96) 6/307.7 1.95 (0.88–4.27)
100–199 9/136.5 6.59 (3.43–12.6) 6/167.5 3.58 (1.61–7.98)
200 11/65.2 16.8 (9.34–30.5) 8/108.5 7.38 (3.69–14.7)
Renal All 14/1041.1 1.34 (0.8–2.27) 11/897.8 1.23 (0.68–2.21)
34 0/422.4 0 0/310.5 0
34–99 1/417.1 0.24 (0.03–1.70) 0/307.7 0
100 13/201.7 6.44 (3.74–11.1) 11/275.9 4.0 (2.21–7.2)
Nonrenal All 24/1041.2 2.31 (1.55–3.43) 12/897.8 1.34 (0.76–2.35)
34 3/422.4 0.71 (0.23–2.20) 3/310.5 0.97 (0.31–3.0)
34–99 14/417.1 3.36 (2.0–5.67) 6/307.2 1.96 (0.88–4.34)
100 7/201.7 3.47 (1.65–7.28) 3/275.9 1.09 (0.35–3.37)
Cardiovascular All 18/1041.23 1.73 (1.09–2.74) 10/897.8 1.11 (0.6–2.07)
34 0/422.4 0 1/310 0.32 (0.05–2.28)
34–99 9/417.1 2.16 (1.12–4.15) 3/307.7 0.98 (0.31–3.02)
100 7/201.7 3.47 (1.65–7.28) 3/275.9 1.09 (0.34–3.37)
Non-renal, non-cardiovascular All 13/1041.2 1.25 (0.72–2.15) 5/897.8 0.56 (0.23–1.34)
34 0/422.4 0 1/310.5 0.32 (0.04–2.29)
34–99 9/417.1 2.16 (1.12–4.15) 3/307.7 0.98 (0.31–3.02)
100 4/201.7 1.98 (0.74–5.28) 1/275.9 0.36 (0.05–2.57)
Table 3. Hazard ratios by category of endpoint; treatment vs. community included people who qualified for, but did
controls adjusted for age, sex and baseline ACR
not receive treatment (because they were not screened,
HR (95% CI), could not access treatment, or did not want it).
treatment vs. controls Despite a good outcome, the results of such a program
All-cause natural death 0.50 (0.36–0.86), P  0.012 could be better. The “intention to treat” analysis under-
Renal 0.43 (0.19–0.96), P  0.038
states the full potential treatment benefit, because34%Non-renal 0.54 (0.21–1.09), P  0.085
Cardiovascular 0.51 (0.23–1.13), P  0.097 of people were taking medicines occasionally, or not at
Non-renal, non-cardiovascular 0.39 (0.14–1.14), P  0.085 all. Hypertension, and therefore eligibility for treatment
even in the absence of albuminuria, should be redefined
as BP 130/80 in this high risk population [10]. Blood
pressure control was not optimum; at two years 44% of
gram. The use of historical controls to estimate treatment the treatment group had BPs 125/70, a desirable level
benefit is also imperfect. First, the courses of the groups for people with renal disease [9]. Control of blood glu-
were not precisely contemporaneous. Second, the con- cose and lipid levels needs to improve. According to the
trols were followed over a background of no treatment HOPE study, application of ACEi treatment in diabetics
and changing treatment, which could not be precisely can be expanded [15]. Finally, wider use of other renal-
delineated. Third, eligibility of controls by ACR levels protective drugs such as angiotensin receptor blocking
was assessed on a single examination, whereas confirma- agents, and possibly higher doses of ACEi in poor re-
tion was required for the treatment group while people sponders, should be applied [16].
with a single elevated blood pressure, but no other eligi- Treatment appeared to be of benefit in people with
bility criteria, were excluded as controls. Fourth, more normal blood pressures at baseline and those with hyper-
than half the control group subsequently entered the tension, in non-diabetics as well as diabetics, and in peo-
treatment program, and having avoided death and renal ple who had previously received ACEi treatment, as
failure in the pre-program era, thus might have defined well as those who had not. Benefit was apparent among
themselves as “survivors,” potentially inflating the treat- people with all categories of overt albuminuria, who
ment program benefit. However, the greater age, more comprised 64% of the treatment group, although not
diabetes, and more severe renal disease in the treatment among the very low death rates of people with lower
group, all survival disadvantages, could contribute to levels of urinary albumin. Finally, treatment appeared
understatement of the program’s benefit. Ultimately, to be more effective in avoiding end points in people
trends in community-based deaths and renal failure sup- with better preserved GFRs. However, the clear im-
provement in blood pressure in people with low ACRsported the marked impact of the program, although the
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Table 4. Numbers of all-cause natural death by patient characteristics and renal function, and hazard ratio, controls vs. treatment,
adjusted for age, sex, and ACR
Controls Treatment
Adjusted Hazard Ratio (95% CI)
Group Treatment vs. ControlsEvents/person-year
BP 140/90 17/433.3 14/503.1 0.55 (0.26–1.14), P  0.106
BP 140/90 21/598 9/395 0.48 (0.20–0.99), P  0.050
Non-diabetics 26/735.1 10/510.2 0.47 (0.22–1.02), P  0.055
Diabetics 13/302.6 14/400.4 0.52 (0.24–1.13), P  0.098
Treatment group, no prior ACEi 38/1041.2 18/662.2 0.60 (0.34–1.06), P  0.079
Treatment group, prior ACEi only 38/1041.2 5/235.6 0.32 (0.14–0.84), P  0.020
ACR 34 3/422.4 3/310.5 1.26 (0.24–6.57), P  0.784
ACR 34 35/618.8 20/587.4 0.43 (0.25–0.76), P  0.004
GFR 60 22/160.5 14/108.5 0.78 (0.39–1.56), P  0.475
GFR 60 16/880.7 9/789.4 0.44 (0.19–1.09), P  0.059
Fig. 2. Unadjusted Kaplan-Meier estimated
survival rates for everyone (A) and those with
a baseline ACR of 34 (B) in the treatment
versus control groups.
and low GFRs people [7, 12, 13, 14] suggest that survival that the reductions in blood pressure, progression of
ACR and loss of GFR that occur with treatment takebenefit will become manifest in these groups over a
longer period of follow-up period. time to translate into measurable survival benefits.
Our data suggest that a terminal end point was avoidedSurvival benefit was reflected in reduced renal and
nonrenal deaths. Reduction in renal deaths has impor- in about 23 people in the treatment cohort: approxi-
mately 13 renal deaths and 10 non-renal deaths. Thus,tant implications for morbidity, mortality and costs, while
the 54% reduction in nonrenal deaths has a tremendous the number of people needed to treat (NNT) over an
average of 3.39 years to avoid a terminal end point wasimpact in terms of premature death avoided or post-
poned. only 11.6, and the NNT to avoid one renal death was
26.7. Thus, the program was both effective and efficientOur demonstration that albuminuria predicts non-
renal as well as renal deaths [4], anticipates a reduction in avoiding unwanted outcomes. It also saved costs. Baker
et al estimated the average annual cost per patient inin natural deaths and renal failure through interventions
that retard the progression of albuminuria. A fall in the treatment cohort over the first three years of the
program was $1,383 [17]; this would fall as people movecardiovascular deaths is expected in view of the antihy-
pertensive and cardiac and vascular-sparing effects of from the start-up to the maintenance phase. Using dial-
ysis cost estimates of You et al [3] and the average sur-ACEi. However, the associations of non-cardiovascular
non-renal deaths with albuminuria and the apparent ben- vival of people on dialysis described by Spencer et al [2],
it was estimated that between $884,400 and $4,057,200efit with treatment lend themselves less readily to tradi-
tional explanations. was saved in those first three years, through avoidance
or postponement of dialysis alone. The range dependsAbout two years of treatment was required before
reduction in all-cause natural death became apparent. on whether ESRD incidence would have plateaued at
the pre-program peak of 2760 per million (pm), or wouldThis reflects, in part, the prioritization of the sickest
people for early entry into the program. It also implies have continued to double every four years in the absence
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Fig. 3. Average annual number of natural
deaths ( ) and new dialysis starts ( ) in Tiwi
adults.
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